SARS-COV-2 Variants: Differences and Potential of Immune Evasion

@article{Hirabara2021SARSCOV2VD,
  title={SARS-COV-2 Variants: Differences and Potential of Immune Evasion},
  author={Sandro Massao Hirabara and T D A Serdan and Renata Gorj{\~a}o and Laureane Nunes Masi and Tania Cristina Pithon-Curi and Dimas Tadeu Covas and Rui Curi and Edison L Durigon},
  journal={Frontiers in Cellular and Infection Microbiology},
  year={2021},
  volume={11}
}
The structural spike (S) glycoprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) plays an essential role in infection and is an important target for neutralizing antibody recognition. Mutations in the S gene can generate variants of concern (VOCs), which improve “viral fitness” through selective or survival advantages, such as increased ACE-2 receptor affinity, infectivity, viral replication, higher transmissibility, resistance to neutralizing antibodies and immune escape… 
View on PubMed
frontiersin.org
27 Citations
Highly Influential Citations
1
Background Citations
9

Figures and Tables from this paper

27 Citations

Citation Type

Citation Type

Immunosuppression as a hub for SARS-CoV-2 mutational drift
TLDR
The findings suggest only minor influence of host parameters on the SARS-CoV-2 intra-host evolutionary rate and trajectory, with even the majority of immunosuppressed persons carrying fairly unremarkable viral genomes.
COVID-19 Genetic Variants and Their Potential Impact in Vaccine Development
TLDR
This work aims to describe the most relevant mutations in the SARS-CoV-2 spike protein, discuss vaccine against variant of concerns, describe rare adverse events after CO VID-19 vaccination, introduce the most available promising COVID-19 vaccine candidates, and provide few perspectives of the future variants.
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant
TLDR
The Omicron variant evades the protection rendered by vaccine-induced antibodies and natural infection, as well as overpowers the antibody-based immunotherapies, raising the concerns of current effectiveness of available vaccines and monoclonal antibody- based therapies.
Assessment of BIV1-CovIran inactivated vaccine–elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern
Clinical Characteristics of COVID-19 Patients Infected by the Omicron Variant of SARS-CoV-2
TLDR
The results supported that the viremic effect of the omicron variant became milder than the previous circulating variants, while full vaccination or booster shot was greatly desired for an effective protection against clinical severity.
Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination
TLDR
Results indicate that anti-RBD IgG levels cannot be used as a predictor for the presence of NAbs against the globally dominant SARS-CoV-2 Omicron variant.
Tracking the circulating SARS-CoV-2 variants in Turkey: Complete genome sequencing and molecular characterization of 1000 SARS-CoV-2 samples
TLDR
This study provides new insights both into the SARS-CoV-2 landscape of Turkey and the transmission of the emerging viral pathogen and its interaction with its vertebrate host.
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates
Highlights Omicron has shown immune escape from neutralizing antibodies generated through previous infection or vaccination. It could evade the protection provided by mAbs being used in clinics for…
Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals
TLDR
In mild SARS-CoV-2-infected individuals, the duration of symptoms and age (but not VL) contribute to higher humoral responses, and non-early seroconverters had lower antibody titers on day 60, albeit similar neutralizing activity as the groups with high or low VL.
An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2
TLDR
Overall, the therapeutic potential of sACE22.v2.4-IgG1 is found to increase survival and ameliorate lung injury in K18-hACE2 transgenic mice inoculated with a lethal dose of the virulent P.1/gamma virus and broad neutralization potency persists against increasingly divergent SARS-CoV-2 variants.
...
...

References

SHOWING 1-10 OF 145 REFERENCES
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
SARS-CoV-2 variants, spike mutations and immune escape
TLDR
The literature on mutations of the SARS-CoV-2 spike protein, the primary antigen, is summarized, focusing on their impacts on antigenicity and contextualizing them in the protein structure, and discussed in the context of observed mutation frequencies in global sequence datasets.
The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
TLDR
The finding from the in vitro assay suggest that Omicron variant may lead to more significant escape from immune protection elicited by previous SARS-CoV-2 infection and perhaps even by existing COVID-19 vaccines.
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
TLDR
Sera from individuals having received one dose of Pfizer or AstraZeneca vaccines barely inhibited variant Delta, and it was found that variant Delta spread is associated with an escape to antibodies targeting non-RBD and RBD Spike epitopes.
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
TLDR
The susceptibility of these newly emerged variants to BNT162b2 vaccine-elicited neutralization supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic across geographies.
Enhancing host cell infection by SARS-CoV-2
TLDR
It is shown that the membrane protein neuropilin-1 (NRP1) promotes SARS-CoV-2 entry and how NRP1 interacts with the S-protein-S protein suggested as a potential antiviral target is explained.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
TLDR
A lentivirus-based pseudovirus assay is employed to show that SARS-CoV-2 Spike variant B.1.1-1.7 remains sensitive to neutralization, albeit at moderately reduced levels, by serum samples from convalescent individuals and recipients of two different vaccines based on ancestral Spike.
Antibody evasion by the P.1 strain of SARS-CoV-2
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
...
...